Gabather Past Earnings Performance
Past criteria checks 0/6
Gabather has been growing earnings at an average annual rate of 11.4%, while the Pharmaceuticals industry saw earnings growing at 9.3% annually. Revenues have been declining at an average rate of 21.8% per year.
Key information
11.4%
Earnings growth rate
32.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | -21.8% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Gabather makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -11 | 11 | 0 |
| 31 Mar 24 | 0 | -11 | 11 | 0 |
| 31 Dec 23 | 0 | -9 | 9 | 0 |
| 30 Sep 23 | 0 | -9 | 9 | 0 |
| 30 Jun 23 | 0 | -8 | 8 | 0 |
| 31 Mar 23 | 0 | -9 | 9 | 0 |
| 31 Dec 22 | 0 | -9 | 9 | 0 |
| 30 Sep 22 | 0 | -11 | 11 | 0 |
| 30 Jun 22 | 0 | -13 | 13 | 0 |
| 31 Mar 22 | 0 | -15 | 15 | 0 |
| 31 Dec 21 | 0 | -17 | 17 | 0 |
| 30 Sep 21 | 0 | -15 | 15 | 0 |
| 30 Jun 21 | 0 | -16 | 15 | 0 |
| 31 Mar 21 | 0 | -14 | 14 | 0 |
| 31 Dec 20 | 0 | -15 | 15 | 0 |
| 30 Sep 20 | 0 | -15 | 15 | 0 |
| 30 Jun 20 | 0 | -13 | 13 | 0 |
| 31 Mar 20 | 0 | -15 | 15 | 0 |
| 31 Dec 19 | 0 | -14 | 14 | 0 |
| 30 Sep 19 | 0 | -15 | 14 | 0 |
| 30 Jun 19 | 0 | -17 | 17 | 0 |
| 31 Mar 19 | 0 | -19 | 19 | 0 |
| 31 Dec 18 | 0 | -20 | 20 | 0 |
| 30 Sep 18 | 0 | -21 | 21 | 0 |
| 30 Jun 18 | 0 | -19 | 20 | 0 |
| 31 Mar 18 | -1 | -15 | 18 | 0 |
| 31 Dec 17 | 0 | -14 | 17 | 0 |
| 30 Sep 17 | 0 | -12 | 15 | 0 |
| 30 Jun 17 | 0 | -10 | 12 | 0 |
| 31 Mar 17 | 1 | -9 | 11 | 0 |
| 31 Dec 16 | 0 | -8 | 8 | 0 |
| 30 Sep 16 | 0 | -7 | 7 | 0 |
| 30 Jun 16 | 0 | -7 | 7 | 0 |
| 31 Mar 16 | 0 | -6 | 6 | 0 |
| 31 Dec 15 | 0 | -6 | 6 | 0 |
Quality Earnings: GABA is currently unprofitable.
Growing Profit Margin: GABA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GABA is unprofitable, but has reduced losses over the past 5 years at a rate of 11.4% per year.
Accelerating Growth: Unable to compare GABA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GABA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.5%).
Return on Equity
High ROE: GABA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.